Helix BioPharma Corp. Announces Third Quarter Fiscal 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Helix BioPharma Corp. Announces Third Quarter Fiscal 2016 Results

AURORA, ON--(Marketwired - Jun 14, 2016) - Helix BioPharma Corp. ( TSX : HBP ) ( FRANKFURT : HBP ), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the third quarter of fiscal 2016, ended April 30, 2016.

HIGHLIGHTS

  • The Company successfully completed enrolment in its Phase I study of L-DOS47 in non-small cell lung cancer. After reviewing the Phase I safety data, the Trial Steering Committee recommended the initiation of the Phase II study.
  • The Company dosed its first patient in its Phase II study of L-DOS47 in non-small cell lung cancer in Poland;
  • The Company closed a private placement for gross proceeds of approximately $4.7 million;
  • The Company's Polish subsidiary, Helix Polska, qualified for approximately $4.1 million in grant money from the Polish National Center for Research and Development;
  • Dr. Sven Rohmann was appointed to the position of Chief Executive Officer of Helix BioPharma Corp., as well as Chairman of the Company's Polish subsidiary, Helix Polska; and
  • Dr. Patrick Frankham was appointed Chief Operating Officer and Steve Demas was promoted to Chief Medical Officer.

FINANCIAL REVIEW

The Company recorded a net loss and total comprehensive loss of $2,243,000 and $7,061,000, respectively for the three and nine-month periods ended April 30, 2016 for a loss per common share of $0.02 and $0.08, respectively. For the comparative three and nine-month periods ended April 30, 2015, the Company recorded a net loss and total comprehensive loss of $1,821,000 and $6,611,000, respectively for a loss per common share of $0.03 and $0.09, respectively.

Research and development

Research and development costs totalled $1,507,000 and $4,092,000, respectively for the three and nine-month periods ended April 30, 2016. For the three and nine-month periods ended April 30, 2015, research and development costs totalled $1,216,000 and $3,902,000, respectively.

Research and development expenses for the three and nine-month periods ended April 30, 2016 when compared to the three and nine month periods ended April 30, 2015 were impacted by higher contract research organization costs related to the European Phase I/II clinical study in Poland and costs associated with the Phase I clinical trial of LDOS001 in the U.S. The same factors above impacted research and development spend for the nine-month periods ended April 30, 2016 and 2015, but were offset by lower contract manufacturing expenditures in the current year-to-date. The Company in the current fiscal quarter accrued an amount likely payable to the consulting group involved in the Company's successful qualification for grant money from the Polish National Center for Research and Development.

Operating, general and administration

Operating, general and administration expenses for the three and nine-month periods ended April 30, 2016 totalled $748,000 and $2,964,000, respectively ($687,000 and $2,754,000 respectively for the three and nine-month periods ended April 30, 2015). Higher operating, general and administration expenses for the three month period ended April 30, 2016 when compared to the three month period ended April 30, 2015 is the result of higher travel fees associated with business development activities, higher legal fees related to the Company's Polish subsidiary and slightly higher director fees which were partially offset by lower third party consulting costs. For the nine month period ended April 30, 2016 when compared to the nine month period ended April 30, 2015, the same factors mentioned above also impacted operating, general and administration expenses with third party consulting costs contributing to the higher spend on a year-to-date basis.

LIQUIDITY AND CAPITAL RESOURCES

The Company's cash reserves of $4,929,000, as at April 30, 2016, are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current research and development initiatives through to completion. Management therefore considers securing additional funds, expected to be through the issuance of equity securities of the Company, to be of the utmost importance.

The Company's condensed unaudited interim consolidated statement of net loss and comprehensive loss for the three and nine-month periods ending April 30, 2016 and 2015 and the condensed unaudited interim consolidated statement of cash flows for the nine-month periods ending April 30, 2016 and 2015 are summarized below:

                             
Consolidated Statements of Net Loss and Comprehensive Loss            
(thousand $, except for per share data)                        
                             
    For the three-month periods ended     For the nine-month periods ended      
    Apr-30     Apr-30     Apr-30     Apr-30      
    2016     2015     2016     2015      
                                     
Expenses:                                    
  Research and development     1,507       1,216       4,092       3,902      
  Operating, general, administration     748       687       2,964       2,754      
Results from operating activities before finance items     (2,255 )     (1,903 )     (7,056 )     (6,656 )    
                                     
Finance items     12       32       (5 )     (5 )    
                                     
                                     
Loss and total comprehensive loss     (2,243 )     (1,871 )     (7,061 )     (6,661 )    
                                     
Gain - sale of discontinued operations     -       50       -       50      
                                     
Loss and total comprehensive loss     (2,243 )     (1,821 )     (7,061 )     (6,611 )    
                                     
Loss per share *   $ (0.02 )   $ (0.03 )   $ (0.08 )   $ (0.09 )    
                                     
* Figures are for both basic and fully diluted                              
                                     
                                     
                                     
               
  Consolidated Statements of Cash Flows            
  (thousand $)            
               
      For the nine-month periods ended    
      Apr-30   Apr-30    
      2016   2015    
               
  Cash provided by (used in):            
  Net loss and total comprehensive loss   (7,061 ) (6,661 )  
               
  Items not involving cash:            
    Depreciation   105   105    
    Stock-based compensation   195   362    
    Foreign exchange loss   14   33    
               
      (6,747 ) (6,161 )  
               
  Changes in non-cash working capital   750   17    
               
  Operating activities   (5,997 ) (6,144 )  
               
  Financing activities   4,176   8,310    
               
  Investing activities   (28 ) (12 )  
               
  Exchange rate changes on cash   (14 ) (33 )  
               
  Net increase (decrease) in cash   (1,863 ) 2,121    
  from continuing operations            
               
  Increase in cash from discontinued operations -   50    
               
  Cash beginning of the period   6,792   6,980    
               
  Cash end of the period   4,929   9,151    
               

The Company's condensed unaudited interim consolidated statement of financial position as at April 30, 2016 and July 31, 2015 are summarized below:

       
Consolidated Statement of Financial Position (thousand $)    
       
  30-Apr-16   31-Jul-15
       
Non current assets 252   329
       
Current assets:      
  Prepaids 160   184
  Accounts receivable 242   491
  Cash 4,929   6,792
  5,331   7,467
       
Total assets 5,583   7,796
       
Shareholders' equity 4,137   6,827
       
Current liabilities:      
  Accrued liabilities 630   707
  Accounts payable 816   262
  1,446   969
       
Total liabilities & shareholders equity 5,583   7,796
       
       

The Company's condensed unaudited interim consolidated financial statements and management's discussion and analysis will be filed under the Company's profile on SEDAR at www.sedar.com , as well as on the Company's website at www.helixbiopharma.com . Shareholders have the ability to receive a hard copy of the Company's unaudited condensed interim consolidated financial statements free of charge upon request at the address below.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Information and Risks and Uncertainties

This news release contains forward-looking information (collectively, "forward-looking information") within the meaning of applicable Canadian securities laws. Forward-looking information includes statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47, and other information in future periods.

Forward-looking information includes, without limitation, statements concerning the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing and future expenditures, the insufficiency of the Company's current cash resources and the need for financing. Forward-looking information can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking information are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking information, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies, or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; and the timely receipt of required regulatory approvals and strategic partner support.

The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in Helix's Annual Information Form, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under the Company's profile on SEDAR at www.sedar.com from time to time. Forward-looking information is based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and the Company does not assume any obligation to update any forward-looking information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

Investor Relations: Helix BioPharma Corp. 3-305 Industrial Parkway South Aurora, Ontario, L4G 6X7 Tel: 905 841-2300 Fax: (905) 841-2244 Email: ir@helixbiopharma.com Web: www.helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading